Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

• Status: Terminated
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gynecologic Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Methylene Blue; Technetium Tc 99m Sulfur Colloid

Criteria

Inclusion Criteria:

• Diagnosis of carcinoma of the cervix of 1 of the following cellular types:

• Squamous cell carcinoma

• Adenocarcinoma

• Adenosquamous cell carcinoma

• Stage IB1 disease (no greater than 4 cm)

• No unequivocal evidence of metastases

• Adequate surgical candidate

• No known allergy to triphenylmethane compounds

• No prior pelvic irradiation

• No prior retroperitoneal surgery

• More than 4 weeks since prior cold knife or loop electrosurgical excision procedure (LEEP) cone biopsy

• Prior cone biopsy allowed provided current disease is stage IB1